Table 3.

Changes in the number of pigs developing porcine circovirus type 2 (PCV2) and wild-type classical swine fever virus (CSFV) viremia in various treatment groups over time after CSFV challenge^a.

dpi	27	30	33	36	39	42	45
Group 1	6/0/6b	6/3/6	6/2/6	6/1/6	6/1/6	6/1/6	6/0/6
Group 2	6/0/6	6/6/6	6/6/6	6/6/6	4/4/4	1/1/1	0/0/0
Group 3	0/0/3	0/0/3	0/0/3	0/0/3	0/0/3	0/0/3	0/0/3
Group 4	0/0/3	0/3/3	0/3/3	0/3/3	0/3/3	0/3/3	0/0/0

Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and group 4: CSFV-challenged.

^aThe pigs were inoculated with 10^5.3 TCID₅₀ of PCV2 (group 1 and 2), 1 dose of LPC vaccine (group 1 and 3), and 10^6.8 TCID₅₀ of wild-type CSFV (ALD) (group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively. The PCV2 and wild-type CSFV loads in plasma were detected by real-time PCR or reverse transcription real-time PCR, respectively.

^bNumber of PCV2-positive animals/number of wild-type CSFV-positive animals/number of surviving animals.